AI-powered Drug Discovery Startups

Parallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery. The company aims to accelerate pharmaceutical development and reduce clinical trial failure rates through human-first biological prediction models.

9 investors

Nabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines. The company focuses on making drug development more systematic and iterative, serving the pharmaceutical and biotech industry.

6 investors

Persephone Biosciences develops a synbiotic (probiotic and prebiotic combination) supplement for infants designed to replenish key beneficial gut bacteria. The product targets parents seeking to support their babies' digestive health, immune development, and overall microbiome health.

6 investors

Shiru uses AI and material science to discover natural proteins and ingredients for use in food, personal care, agriculture, and advanced materials, reducing traditional development timelines from 5-15 years to 1-2 years.

6 investors

Adaptyv Bio develops technologies for protein engineering that enable the design and testing of new proteins for applications in medicine, industrial enzymes, and functional materials. The company serves protein engineers and researchers developing therapeutic and industrial biological products.

5 investors

Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.

5 investors

Reverie Labs develops cancer treatments designed to cross the blood-brain barrier and treat tumors in the central nervous system.

5 investors

SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.

5 investors

CellChorus develops a visual AI platform called TIMING that performs high-throughput dynamic analysis of single cells, measuring cell activation, killing, and movement over time for biopharmaceutical research. The company serves biopharmaceutical companies and therapy developers seeking to understand cellular function and phenotype.

4 investors

Menten AI develops generative AI software to design cyclic peptide therapeutics for drug targets beyond the reach of conventional small molecules and biologics. The company partners with major pharmaceutical firms to accelerate preclinical drug discovery.

4 investors

Numerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.

4 investors

Output builds generative AI models trained on biological data to discover and develop medicines. The company focuses on applying large biological models to improve diagnosis, treatment, and disease prevention.

4 investors

Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.

3 investors

Ångström AI develops AI-powered physics simulations for pharmaceutical drug discovery, computing molecular properties like solubility, lipophilicity, and crystal structure stability to replace traditional lab experiments. The platform uses machine learning interatomic potentials and free energy calculations to accelerate and derisk solid form development for pharma companies.

3 investors

b12 develops AI agents and lab automation software to help chemists plan, optimize, and execute the synthesis of complex molecules. The platform combines chemistry expertise with agentic AI systems to streamline organic synthesis workflows.

3 investors

Diffuse designs proteins using AI models trained on experimental data collected through proprietary assays and software, delivering validated AI-designed proteins to partners.

3 investors

Harmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.

3 investors

Lavo Life Sciences offers computational molecular simulations to pharmaceutical companies, helping them optimize drug formulations, reduce experimental costs, and accelerate the path to clinical trials and regulatory approval.

3 investors

Nanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.

3 investors

1910 develops an AI platform that integrates multimodal data, frontier AI models, and high-throughput lab automation to accelerate drug discovery and development for pharmaceutical companies. The platform targets undruggable targets and aims to improve R&D productivity in the biopharma industry.

2 investors

PipeBio provides a bioinformatics platform for drug discovery that enables scientists and bioinformaticians to analyze genomic and assay data. The platform combines sequence data management, machine learning tools, and visualization capabilities to accelerate therapeutic development for academia, biotech companies, and pharmaceutical firms.

2 investors

Qvin develops the Q-Pad, an FDA-cleared diagnostic menstrual pad that collects menstrual blood samples for non-invasive health monitoring and disease diagnosis. The company uses biomarker analysis from menstrual fluid to serve healthcare organizations and diagnostic platforms in women's health diagnostics.

2 investors

ResistanceBio develops treatments to address drug resistance in cancer patients.

2 investors

2 investors